Request that the FDA determine and declare that Buspirone Capsules 2.5 mg, 12.5 mg, 20 mg and 30 mg is suitable for submission in an Abbreviated New Drug Application (ANDA)
🏛 Food and Drug Administration (FDA)FDA-2026-P-7195
Documents
8
Total comments
0
all analyzed
Comment status
Open
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
📄 Primary document
- Other· Jun 30, 2026No comment period
- Other· Jun 30, 2026No comment period
- Supporting & Related Material· Jun 30, 2026
- Supporting & Related Material· Jun 30, 2026
- Supporting & Related Material· Jun 30, 2026
- Supporting & Related Material· Jun 30, 2026
- Supporting & Related Material· Jun 30, 2026